Assessment of leukocyte and systemic inflammation index ratios in dyslipidemia patients with dry eye disease: a retrospective case‒control study.
Humans
Dyslipidemias
/ blood
Male
Female
Dry Eye Syndromes
/ blood
Middle Aged
Inflammation
/ blood
Case-Control Studies
Retrospective Studies
Biomarkers
/ blood
Aged
Cholesterol, HDL
/ blood
Triglycerides
/ blood
C-Reactive Protein
/ metabolism
Leukocytes
/ metabolism
Lymphocytes
Neutrophils
/ metabolism
Cholesterol, LDL
/ blood
Adult
Blood Platelets
/ pathology
Dry eye disease
Dyslipidemia
Inflammatory blood biomarkers
Leukocytes
Systemic inflammation index ratios
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
received:
21
02
2024
accepted:
04
06
2024
medline:
12
6
2024
pubmed:
12
6
2024
entrez:
11
6
2024
Statut:
epublish
Résumé
Dry eye disease (DED) is a complication of dyslipidemia (DLP) that is caused by metabolic syndrome and increased inflammation. This research aimed to assess leukocyte and systemic inflammation index ratios as potential biomarkers for systemic inflammation in dyslipidemia patients with dry eye disease (DLP-DED). Several blood biomarkers were studied in 32 patients with DLP-DED (study group) and 63 patients with DLP-only (control group). The evaluated blood biomarkers included specific systemic inflammation index ratios, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and neutrophil-to-lymphocyte and platelet ratio (NLPR), and lipid profiles, such as total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglyceride (TG), albumin (ALB), and C-reactive protein (CRP) levels. Lymphocyte levels were significantly greater in the DLP-DED group than in the DLP-only group (P = 0.044). In addition, a significant negative correlation between HDL and the NLPR (P = 0.007; r= -0.428) and a significant negative correlation between the serum ALB concentration and the PLR (P = 0.008; r= -0.420) were identified as potential inflammatory predictors of DLP-DED. The findings of this study suggest that patients with DLP-DED may benefit from routine blood monitoring of their elevated lipid profile and blood inflammatory biomarkers, such as CRP, leukocytes, and systemic inflammation index ratios (NLR, PLR, MLR, and NLPR), to reduce the complications of DLP on ocular health. The correlation data suggest that the NLPR, PLR, serum ALB concentration, and serum HDL concentration may be valuable inflammatory biomarkers in DLP-DED patients. More research is required to ascertain the significance of the NLR, PLR, MLR, and NLPR and the additive role that leukocytes play.
Sections du résumé
BACKGROUND
BACKGROUND
Dry eye disease (DED) is a complication of dyslipidemia (DLP) that is caused by metabolic syndrome and increased inflammation. This research aimed to assess leukocyte and systemic inflammation index ratios as potential biomarkers for systemic inflammation in dyslipidemia patients with dry eye disease (DLP-DED).
METHODS
METHODS
Several blood biomarkers were studied in 32 patients with DLP-DED (study group) and 63 patients with DLP-only (control group). The evaluated blood biomarkers included specific systemic inflammation index ratios, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and neutrophil-to-lymphocyte and platelet ratio (NLPR), and lipid profiles, such as total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglyceride (TG), albumin (ALB), and C-reactive protein (CRP) levels.
RESULTS
RESULTS
Lymphocyte levels were significantly greater in the DLP-DED group than in the DLP-only group (P = 0.044). In addition, a significant negative correlation between HDL and the NLPR (P = 0.007; r= -0.428) and a significant negative correlation between the serum ALB concentration and the PLR (P = 0.008; r= -0.420) were identified as potential inflammatory predictors of DLP-DED.
CONCLUSION
CONCLUSIONS
The findings of this study suggest that patients with DLP-DED may benefit from routine blood monitoring of their elevated lipid profile and blood inflammatory biomarkers, such as CRP, leukocytes, and systemic inflammation index ratios (NLR, PLR, MLR, and NLPR), to reduce the complications of DLP on ocular health. The correlation data suggest that the NLPR, PLR, serum ALB concentration, and serum HDL concentration may be valuable inflammatory biomarkers in DLP-DED patients. More research is required to ascertain the significance of the NLR, PLR, MLR, and NLPR and the additive role that leukocytes play.
Identifiants
pubmed: 38862998
doi: 10.1186/s12944-024-02176-z
pii: 10.1186/s12944-024-02176-z
doi:
Substances chimiques
Biomarkers
0
Cholesterol, HDL
0
Triglycerides
0
C-Reactive Protein
9007-41-4
Cholesterol, LDL
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
179Informations de copyright
© 2024. The Author(s).
Références
Kopin L, Lowenstein CJ, Dyslipidemia. Ann Intern Med. 2017;167(11):ITC81–96.
pubmed: 29204622
doi: 10.7326/AITC201712050
Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15(3):575–628.
pubmed: 28736343
doi: 10.1016/j.jtos.2017.05.006
Bafei SEC, Zhao X, Chen C, Sun J, Zhuang Q, Lu X, et al. Interactive effect of increased high sensitive C-reactive protein and dyslipidemia on cardiovascular diseases: a 12-year prospective cohort study. Lipids Health Dis. 2023;22(1):95.
pubmed: 37403063
pmcid: 10318784
doi: 10.1186/s12944-023-01836-w
Dongway AC, Faggad AS, Zaki HY, Abdalla BE. C-reactive protein is associated with low-density lipoprotein cholesterol and obesity in type 2 diabetic Sudanese. Diabetes Metabolic Syndrome Obesity: Targets Therapy. 2015;8:427–35.
pubmed: 26379442
Wu L, Parhofer KG. Diabetic dyslipidemia. Metab Clin Exp. 2014;63(12):1469–79.
pubmed: 25242435
doi: 10.1016/j.metabol.2014.08.010
Mavromati M, Jornayvaz FR. Hypothyroidism-Associated Dyslipidemia: potential molecular mechanisms leading to NAFLD. Int J Mol Sci. 2021;22(23).
Yang W, Yang K, Pan Y, Wu S, Chen X, Shen L, et al. A literature-derived dataset on risk factors for dry eye disease. Sci Data. 2023;10(1):21.
pubmed: 36631463
pmcid: 9834299
doi: 10.1038/s41597-023-01931-8
Hong N, Lin Y, Ye Z, Yang C, Huang Y, Duan Q, et al. The relationship between dyslipidemia and inflammation among adults in east coast China: a cross-sectional study. Front Immunol. 2022;13:937201.
pubmed: 36032093
pmcid: 9403313
doi: 10.3389/fimmu.2022.937201
AlMuhaidib S, AlBuhairan F, Tamimi W, AlDubayee M, AlAqeel A, Babiker A, et al. Prevalence and factors associated with dyslipidemia among adolescents in Saudi Arabia. Sci Rep. 2022;12(1):16888.
pubmed: 36207522
pmcid: 9547070
doi: 10.1038/s41598-022-21262-9
Pan L, Yang Z, Wu Y, Yin R-X, Liao Y, Wang J, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis. 2016;248:2–9.
pubmed: 26978581
doi: 10.1016/j.atherosclerosis.2016.02.006
Kolovou GD, Anagnostopoulou KK, Damaskos DS, Bilianou HI, Mihas C, Milionis HJ, et al. Gender differences in the lipid profile of dyslipidemic subjects. Eur J Intern Med. 2009;20(2):145–51.
pubmed: 19327602
doi: 10.1016/j.ejim.2008.06.011
Correa R, Wayar F, Reaven P, Corpas E. Dyslipidemia in the Elderly. Endocrinology of Aging: Elsevier; 2021. pp. 607–50.
Vekic J, Stefanovic A, Zeljkovic A. Obesity and dyslipidemia: a review of current evidence. Curr Obes Rep. 2023:1–16.
Alamri S, Almalki MD, Alotaibi WN, Althobaiti S. The prevalence of dyslipidemia in obese patients. Int J Med Developing Ctries. 2019;3(1):006–9.
doi: 10.24911/IJMDC.51-1544193916
Kim K-i. Dyslipidemia in older adults and management of dyslipidemia in older patients. J Lipid Atherosclerosis. 2015;4(1):1–6.
doi: 10.12997/jla.2015.4.1.1
McCulley JP, Shine W. A compositional based model for the tear film lipid layer.A compositional based model for the tear film lipid layer. Trans Am Ophthalmol Soc. 1997;95:79–93.
pubmed: 9440164
pmcid: 1298352
Osae EA, Steven P, Redfern R, Hanlon S, Smith CW, Rumbaut RE et al. Dyslipidemia and Meibomian Gland Dysfunction: utility of Lipidomics and experimental prospects with a Diet-Induced obesity mouse model. Int J Mol Sci. 2019;20(14).
Chun YH, Kim HR, Han K, Park YG, Song HJ, Na KS. Total cholesterol and lipoprotein composition are associated with dry eye disease in Korean women. Lipids Health Dis. 2013;12:84.
pubmed: 23734839
pmcid: 3680171
doi: 10.1186/1476-511X-12-84
Tavares Fde P, Fernandes RS, Bernardes TF, Bonfioli AA, Soares EJ. Dry eye disease. Semin Ophthalmol. 2010;25(3):84–93.
pubmed: 20590418
doi: 10.3109/08820538.2010.488568
Dao AH, Spindle JD, Harp BA, Jacob A, Chuang AZ, Yee RW. Association of dyslipidemia in moderate to severe meibomian gland dysfunction. Am J Ophthalmol. 2010;150(3):371–5.
pubmed: 20619393
doi: 10.1016/j.ajo.2010.04.016
Wang T-H, Tsai Y-J, Wang Y-H, Wu C-L, Lin I-C. Relationship between Dry Eye Disease and Dyslipidemia: a systematic review. J Clin Med. 2023;12(20):6631.
pubmed: 37892769
pmcid: 10607063
doi: 10.3390/jcm12206631
Wang TJ, Wang IJ, Hu CC, Lin HC. Comorbidities of dry eye disease: a nationwide population-based study. Acta Ophthalmol. 2012;90(7):663–8.
pubmed: 20809911
doi: 10.1111/j.1755-3768.2010.01993.x
Blaton V. How is the metabolic syndrome related to the Dyslipidemia? Ejifcc. 2007;18(1):15–22.
pubmed: 29632463
pmcid: 5875077
Swastini DA, Wiryanthini IAD, Ariastuti NLP, Muliantara A. Atherosclerosis prediction with high sensitivity C-reactive protein (hs-CRP) and related risk factor in patient with dyslipidemia. Open Access Macedonian J Med Sci. 2019;7(22):3887.
doi: 10.3889/oamjms.2019.526
Alhalwani AY, Baqar R, Algadaani R, Bamallem H, Alamoudi R, Jambi S et al. Investigating neutrophil-to-lymphocyte and C-Reactive protein-to-albumin ratios in type 2 Diabetic patients with Dry Eye Disease. Ocul Immunol Inflamm. 2023:1–7.
Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Investig. 2003;111(12):1805–12.
pubmed: 12813013
pmcid: 161431
doi: 10.1172/JCI200318921
Sheinenzon A, Shehadeh M, Michelis R, Shaoul E, Ronen O. Serum albumin levels and inflammation. Int J Biol Macromol. 2021;184:857–62.
pubmed: 34181998
doi: 10.1016/j.ijbiomac.2021.06.140
Szabó MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res. 2017;65:543–50.
pubmed: 28168401
doi: 10.1007/s12026-016-8892-9
Popadic V, Brajkovic M, Klasnja S, Milic N, Rajovic N, Lisulov DP, et al. Correlation of dyslipidemia and inflammation with obstructive sleep apnea severity. Front Pharmacol. 2022;13:897279.
pubmed: 35694268
pmcid: 9179947
doi: 10.3389/fphar.2022.897279
Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rhuematol. 2002;29(3):462–6.
Zhang Y, Li S, Xu R-X, Zhu C-G, Guo Y-L, Wu N-Q et al. Systemic inflammatory markers are closely associated with atherogenic lipoprotein subfractions in patients undergoing coronary angiography. Mediators of Inflammation. 2015;2015.
Zhang Y, Li S, Xu R-X, Zhu C-G, Guo Y-L, Wu N-Q, et al. Systemic inflammatory markers are closely Associated with atherogenic lipoprotein subfractions in patients undergoing coronary angiography. Mediat Inflamm. 2015;2015:235742.
doi: 10.1155/2015/235742
Del Rincón I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheumatism: Official J Am Coll Rheumatol. 2003;48(7):1833–40.
doi: 10.1002/art.11078
Sonmez O, Sonmez M. Role of platelets in immune system and inflammation. Porto Biomedical J. 2017;2(6):311–4.
doi: 10.1016/j.pbj.2017.05.005
PaŞAoĞLu Ö, PaŞAoĞLu H. Elevated monocyte to HDL ratio as a new inflammatory marker in patients with dry eye. New Front Ophthalmol. 2018;4(6).
Durmus E, Kivrak T, Gerin F, Sunbul M, Sari I, Erdogan O. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are predictors of Heart failure. Arq Bras Cardiol. 2015;105(6):606–13.
pubmed: 26536980
pmcid: 4693665
Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–72.
pubmed: 28974892
pmcid: 5603492
doi: 10.3748/wjg.v23.i34.6261
Meng Y-F, Pu Q, Ma Q, Zhu W, Li X-Y. Neutrophil/lymphocyte ratio as an inflammatory predictor of dry eye disease: a case-control study. Ther Clin Risk Manag. 2021:259–66.
Ozarslan Ozcan D, Kurtul BE, Ozcan SC, Elbeyli A. Increased systemic immune-inflammation index levels in patients with dry eye disease. Ocul Immunol Inflamm. 2022;30(3):588–92.
pubmed: 32990489
doi: 10.1080/09273948.2020.1821899
Amalia M, Saputri F, Sauriasari R, Widyantoro B. Complete blood count, lipid profiles, and inflammatory markers associated with atherosclerotic cardiovascular disease in patients with diabetes [version 1; peer review: awaiting peer review]. F1000Research. 2023;12(1470).
Ji H, Li Y, Fan Z, Zuo B, Jian X, Li L, et al. Monocyte/lymphocyte ratio predicts the severity of coronary artery disease: a syntax score assessment. BMC Cardiovasc Disord. 2017;17:1–8.
doi: 10.1186/s12872-017-0507-4
Damar Çakırca T, Torun A, Çakırca G, Portakal RD. Role of NLR, PLR, ELR and CLR in differentiating COVID-19 patients with and without pneumonia. Int J Clin Pract. 2021;75(11):e14781.
pubmed: 34482573
doi: 10.1111/ijcp.14781
Fois AG, Paliogiannis P, Scano V, Cau S, Babudieri S, Perra R, et al. The systemic inflammation index on admission predicts in-hospital mortality in COVID-19 patients. Molecules. 2020;25(23):5725.
pubmed: 33291581
pmcid: 7731255
doi: 10.3390/molecules25235725
Ghobadi H, Mohammadshahi J, Javaheri N, Fouladi N, Mirzazadeh Y, Aslani MR. Role of leukocytes and systemic inflammation indexes (NLR, PLR, MLP, dNLR, NLPR, AISI, SIR-I, and SII) on admission predicts in-hospital mortality in non-elderly and elderly COVID-19 patients. Front Med. 2022;9:916453.
doi: 10.3389/fmed.2022.916453
Alhalwani AY, Jambi S, Borai A, Khan MA, Almarzouki H, Elsayid M, et al. Assessment of the systemic immune-inflammation index in type 2 diabetic patients with and without dry eye disease: a case‐control study. Health Sci Rep. 2024;7(5):e1954.
pubmed: 38698793
pmcid: 11063262
doi: 10.1002/hsr2.1954
Elbeyli A, Kurtul BE, Ozcan DO, Ozcan SC, Dogan E. Assessment of red cell distribution width, platelet/lymphocyte ratio, systemic immune-inflammation index, and neutrophil/lymphocyte ratio values in patients with central retinal artery occlusion. Ocul Immunol Inflamm. 2022;30(7–8):1940–4.
pubmed: 34524949
doi: 10.1080/09273948.2021.1976219
Yılmaz Tuğan B, Ergen A, Özkan B. Monocyte-to-high-density lipoprotein ratio and systemic immune-inflammation index: potential parameters for the evaluation of disease activity and severity in Graves’ ophthalmopathy? Int Ophthalmol. 2024;44(1):1–9.
doi: 10.1007/s10792-024-03077-x
Rathnakumar K, Ramachandran K, Baba D, Ramesh V, Anebaracy V, Vidhya R, et al. Prevalence of dry eye disease and its association with dyslipidemia. J Basic Clin Physiol Pharmacol. 2018;29(2):195–9.
pubmed: 29150990
doi: 10.1515/jbcpp-2017-0001
Chun YH, Kim HR, Han K, Park Y-G, Song HJ, Na K-S. Total cholesterol and lipoprotein composition are associated with dry eye disease in Korean women. Lipids Health Dis. 2013;12(1):1–8.
doi: 10.1186/1476-511X-12-84
Alfhili MA, Alsughayyir J, Basudan AM, Alsubki R, Alqahtani S, Awan ZA, et al. editors. Monocyte–lymphocyte ratio and dysglycemia: a Retrospective, cross-sectional study of the Saudi Population. MDPI; 2022.
Li Y, Zou Z, Zhang Y, Zhu B, Ning Y, Shen B, et al. Dynamics in perioperative neutrophil-to-lymphocyte* platelet ratio as a predictor of early acute kidney injury following cardiovascular surgery. Ren Fail. 2021;43(1):1012–9.
pubmed: 34187280
pmcid: 8260043
doi: 10.1080/0886022X.2021.1937220
Kolovou GD, Anagnostopoulou K, Pilatis ND, Salpea KD, Hoursalas IS, Petropoulos I, et al. Fasting serum triglyceride and high-density lipoprotein cholesterol levels in patients intended to be treated for dyslipidemia. Vasc Health Risk Manag. 2005;1(2):155–61.
pubmed: 17315402
pmcid: 1993943
doi: 10.2147/vhrm.1.2.155.64079
Kolovou GD, Anagnostopoulou KK, Pilatis N, Kafaltis N, Sorodila K, Psarros E, et al. Low fasting low high-density lipoprotein and postprandial lipemia. Lipids Health Dis. 2004;3(1):1–8.
doi: 10.1186/1476-511X-3-18
Rubins HB, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, et al. Clinical Investigation and Reports-Reduction in Stroke with Gemfibrozil in Men with Coronary Heart Disease and low HDL cholesterol: the Veterans affairs HDL intervention trial (VA-HIT). Circulation-Hagertown. 2001;103(23):2828–33.
doi: 10.1161/01.CIR.103.23.2828
Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118(9):1264–8.
pubmed: 10980773
doi: 10.1001/archopht.118.9.1264
Vehof J, Smitt-Kamminga NS, Nibourg SA, Hammond CJ. Sex differences in clinical characteristics of dry eye disease. Ocul Surf. 2018;16(2):242–8.
pubmed: 29317327
doi: 10.1016/j.jtos.2018.01.001
The Epidemiology of Dry Eye Disease: Report of the Epidemiology Subcommittee of the International Dry Eye WorkShop. (2007). The Ocular Surface. 2007;5(2):93–107.
Ferdinand KC. Ethnic, gender, and age-related differences in the treatment of dyslipidemia. Am J Manag Care. 2006;12(5):S400–4.
pubmed: 17112327
Ding J, Sullivan DA. Aging and dry eye disease. Exp Gerontol. 2012;47(7):483–90.
pubmed: 22569356
pmcid: 3368077
doi: 10.1016/j.exger.2012.03.020
Kaysen GA. Biochemistry and biomarkers of Inflamed patients: why look, what to assess. Clin J Am Soc Nephrol. 2009;4(Supplement_1).
von Brühl M-L, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819–35.
doi: 10.1084/jem.20112322
Parren PW, Warmerdam PA, Boeije LC, Arts J, Westerdaal NA, Vlug A, et al. On the interaction of IgG subclasses with the low affinity fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Investig. 1992;90(4):1537–46.
pubmed: 1401085
pmcid: 443201
doi: 10.1172/JCI116022
Vázquez-Mendoza A, Vannan D, Morales EG, González MI, Hernández JLR. Lymphocytes in Dry Eye Disease: IntechOpen London, UK; 2021.
Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes. 2017;10(1):12.
pubmed: 28057051
pmcid: 5217256
doi: 10.1186/s13104-016-2335-5
Abdallah AI, Abdelaziz AA, El-Sayed E-SE-M, Emran TM. Study of neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) as a predictor inflammatory marker for diabetic nephropathy in type 2 diabetic patients. Egypt J Hosp Med. 2018;72(7):4800–7.
doi: 10.21608/ejhm.2018.10137
Celik T. Assessment of Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with Dry Eye Disease. Ocul Immunol Inflamm. 2018;26(8):1219–22.
pubmed: 28910561
doi: 10.1080/09273948.2017.1340486
Alhalwani AY, Abudawood K, Qadizadah ABEA, Jambi S, Sannan NS. Immunoglobulin A levels and its correlation with neutrophil-to-lymphocyte ratio as inflammatory biomarkers for dry eye disease in type 2 diabetes: a retrospective study. Front Immunol.14:1184862.
Meng YF, Pu Q, Ma Q, Zhu W, Li XY. Neutrophil/Lymphocyte ratio as an inflammatory predictor of Dry Eye Disease: a case-control study. Ther Clin Risk Manag. 2021;17:259–66.
pubmed: 33790566
pmcid: 8001663
doi: 10.2147/TCRM.S298156
Hasanefendić B, Šeherčehajić E, Dedić A, Tihić-Kapidžić S, Begović E, Hajro S, et al. Systemic inflammatory indexes (NLR, DNLR, PLR and SII) role in predicting COVID-19 progression. J Health Sci. 2023;13(2):113–7.
Rhee MK, Mah FS. Inflammation in dry eye disease: how do we break the cycle? Ophthalmology. 2017;124(11):S14–9.
pubmed: 29055357
doi: 10.1016/j.ophtha.2017.08.029
Nooh HA, Abdellateif MS, Refaat L, Kandeel EZ, Bayoumi A, Samra M, et al. The role of inflammatory indices in the outcome of COVID-19 cancer patients. Med Oncol. 2022;39:1–14.
doi: 10.1007/s12032-021-01605-8
Choi HR, Lee JH, Lee HK, Song JS, Kim HC. Association between dyslipidemia and dry eye syndrome among the Korean middle-aged population. Cornea. 2020;39(2):161–7.
pubmed: 31517720
doi: 10.1097/ICO.0000000000002133
Eissa M, Shaarawy S, Abdellateif MS. The role of different inflammatory indices in the diagnosis of COVID-19. Int J Gen Med. 2021:7843–53.
Harnoto YO, Assagaf A, Pratiwi DIN, Isa M, Nurrasyidah I, Kusumawardhani E. The Influence of inflammatory factors (IL-6, CRP, NLPR, D-Dimer, LDH) on the PaO2/FiO2 ratio, in patients with severe and critical degrees of COVID-19. Medica Hospitalia: Journal of Clinical Medicine. 2023;10(3):352-8.
Li S, Yu S, Qin J, Peng M, Qian J, Zhou P. Prognostic value of platelet count-related ratios on admission in patients with pyogenic liver abscess. BMC Infect Dis. 2022;22(1):1–8.
doi: 10.1186/s12879-022-07613-x
Cao X, Zhao M, Li H, Xu D, Li M, Zhang X, et al. Three new inflammatory markers C reactive protein to albumin ratio, neutrophil to lymphocyte ratio, and platelet to lymphocyte ratio correlated with relapsing polychondritis disease activity index. Clin Rheumatol. 2021;40(11):4685–91.
pubmed: 34160712
doi: 10.1007/s10067-021-05827-z
Türkkan E, Dağ NÇ, Arabacı Ç, Dikker O, Dağ H. Evaluation of inflammatory hematological ratios (NLR, PLR, MLR and Monocyte/HDL-Cholesterol ratio) in obese adolescents. Iberoamerican J Med. 2022;4(1):11–7.